Evidence map›Paper›PMID 32901872›Full record

ArticleInternational journal of molecular medicine2020

Downregulation of miR‑181b inhibits human colon cancer cell proliferation by targeting CYLD and inhibiting the NF‑κB signaling pathway.

Xifeng Yang, Yao Sun, Ying Zhang, Shan Han

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. AKT and DUBs: a bidirectional relationship.Cellular & molecular biology letters · 2025
    Review
  4. Article
  5. Article
  6. BioMOF-Based Anti-Cancer Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2023
    Review
  7. Article
  8. Article
  9. miRNA in Molecular Diagnostics.Bioengineering (Basel, Switzerland) · 2022
    Review
  10. Review
  11. miR-181b regulates vascular endothelial aging by modulating an MAP3K3 signaling pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Downregulation of mInternational journal of biological sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Xifeng YangDepartment of Medical Oncology, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China.
Yao SunDepartment of Radiotherapy, Yidu Central Hospital of Wei Fang, Qingzhou, Shandong 262500, P.R. China.
Ying ZhangDepartment of Radiotherapy, Yidu Central Hospital of Wei Fang, Qingzhou, Shandong 262500, P.R. China.
Shan HanDepartment of Oncology, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China.
Yidu Central Hospital of Weifang · CNWenzhou Medical University · CNYantaishan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been reported that microRNA (miRNA/miR)‑181b plays an important role in regulating cellular proliferation, invasion and apoptosis in various tumors. However, the role of miR‑181b and its molecular mechanisms in colon cancer cells have not yet been elucidated. The present study thus aimed to investigate the mechanisms of miR‑181b targeting cylindromatosis (CYLD) to regulate the nuclear factor‑κB (NF‑κB) signaling pathway, and to determine its role in colon cancer cell proliferation and apoptosis. For this purpose, miR‑181b was overexpressed and silenced in the SW480 cell line. The cell proliferation and apoptotic rates were determined using a Cell Counting kit and colony formation assays, and Annexin V‑FITC staining, respectively. The expression levels of proteins associated with the NF‑κB signaling pathway and apoptosis were detected by western blot analysis. Furthermore, a dual luciferase assay was applied to confirm the interaction between miR‑181b and CYLD. CYLD was also overexpressed and silenced in the SW480 cell line using a CYLD overexpression plasmid and siRNA technology, respectively. Transfected cells were used for subsequent experiments. In addition, a nude mouse model was established to measure tumor volume and weight. Immunohistochemistry and a TUNEL assay were performed to detect the Ki67 levels and the cell apoptotic rate, respectively. Compared with the control group, miR‑181 silencing or CYLD overexpression significantly attenuated cell proliferation, invasion and migration, and notably increased the proportion of apoptotic cells. Furthermore, the expression levels of Bax and cleaved caspase‑3 were markedly increased, whereas those of Bcl‑2 were significantly decresaed (P<0.05). In addition, the protein expression levels of p‑p65/p65 and p‑IκBα/IκBα were significantly downregulated and upregulated, respectively (P<0.05). Consistent with the results obtained in vitro, in vivo experiments using a nude mouse model yielded similar findings. The aforementioned results indicated that miR‑181b downregulation inhibited human colon cancer cell proliferation by targeting CYLD to attenuate the activity of the NF‑κB signaling pathway.

Indexed as

3' Untranslated RegionsApoptosisCell LineCell Line, TumorCell MovementCell ProliferationColonic NeoplasmsDeubiquitinating Enzyme CYLDDown-RegulationGene Expression Regulation, NeoplasticHCT116 CellsHumansMicroRNAsNF-kappa BRNA, Small InterferingSignal Transduction3' Untranslated RegionsCYLD protein, humanDeubiquitinating Enzyme CYLDMicroRNAsNF-kappa BRNA, Small Interfering

Identifiers

PMID32901872
PMCPMC7521473
OpenAlexW3083003723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.